TCR-like mAbs treatment decreases tumor load in vivo. (A) Schematic illustration of TCR-like mAbs treatment. Two million BLCLs were injected intravenously into NSG mice at week 0 before weekly administration of mAbs (300 μg/mouse) from week 1 onward. (B) Human CD45 (hCD45)-positive BLCLs were detectable in various organs day 7 after injection of BLCLs, indicating BLCL engraftment. (C, D) Mice were killed upon 20% weight loss, and organs were harvested for terminal analysis. Images are representative of gross anatomy and hematoxylin and eosin staining of spleens and livers from mice of each treatment group. Images were taken using Carl Zeiss MIRAX MIDI slide scanner, and analyses were performed using a 3DHISTECH Pannoramic Viewer. Liver tumor spots were traced in black (bottom), using Adobe Photoshop CS6. Scale bars, 500 μm (spleen) and 2000 μm (liver). (E) Spleens were weighed, and (F) the number of liver tumor spots were counted during terminal analysis. Results were expressed as mean ± SD. *P < .05, **P < .01 (unpaired Student t test). Data are representative of 2 independent experiments.